XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Heinz Lubenau, Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter, Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen® BioDrugs. ,vol. 23, pp. 43- 51 ,(2009) , 10.2165/00063030-200923010-00005

M. von Lilienfeld-Toal, C. Hahn-Ast, H. Kirchner, D. Flieger, G. Dolken, A. Glasmacher, A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy Haematologica. ,vol. 92, pp. 1719- 1720 ,(2007) , 10.3324/HAEMATOL.11516

David C Dale, None, Colony-stimulating Factors for the Management of Neutropenia in Cancer Patients Drugs. ,vol. 62, pp. 1- 15 ,(2002) , 10.2165/00003495-200262001-00001

Charles L Vogel, Marek Z Wojtukiewicz, Robert R Carroll, Sergei A Tjulandin, Luis Javier Barajas-Figueroa, Brian L Wiens, Theresa A Neumann, Lee S Schwartzberg, None, First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study Journal of Clinical Oncology. ,vol. 23, pp. 1178- 1184 ,(2005) , 10.1200/JCO.2005.09.102

F.A. Holmes, Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 727- 731 ,(2002) , 10.1200/JCO.20.3.727

Arien Termeer, Cornelis A. Hensing, Janine Akkermans, Eddy M. Adang, Geeben P. Bootsma, Vivianne C. Tjan-Heijnen, Johanna N. Timmer-Bonte, Theo M. de Boo, Hans J. Smit, Bonne Biesma, Frank A. Wilschut, Samia A. Cheragwandi, Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study Journal of Clinical Oncology. ,vol. 23, pp. 7974- 7984 ,(2005) , 10.1200/JCO.2004.00.7955

George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak, Antonio C. Wolff, Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline Journal of Clinical Oncology. ,vol. 24, pp. 3187- 3205 ,(2006) , 10.1200/JCO.2006.06.4451

Etienne GC Brain, Thomas Bachelot, Daniel Serin, Sylvie Kirscher, Yvon Graic, Jean-Christophe Eymard, Jean-Marc Extra, Martin Combe, Emmanuelle Fourme, Catherine Noguès, Jacques Rouëssé, RAPP-01 Trial Investigators, Life-Threatening Sepsis Associated With Adjuvant Doxorubicin Plus Docetaxel for Intermediate-Risk Breast Cancer JAMA. ,vol. 293, pp. 2367- 2371 ,(2005) , 10.1001/JAMA.293.19.2367

Matti S Aapro, David A Cameron, Ruth Pettengell, Julia Bohlius, Jeffrey Crawford, Michael Ellis, Nora Kearney, Gary H Lyman, Vivianne C Tjan-Heijnen, Jan Walewski, DC Weber, Christoph Zielinski, European Organisation for Research, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours European Journal of Cancer. ,vol. 42, pp. 2433- 2453 ,(2006) , 10.1016/J.EJCA.2006.05.002

Françoise Martin-Christin, Granulocyte colony stimulating factors: how different are they? How to make a decision? Anti-Cancer Drugs. ,vol. 12, pp. 185- 191 ,(2001) , 10.1097/00001813-200103000-00002